Thrombolysis and hemorrhagic transformation.
De Keyser
Jacques
J
D000208:Acute Disease; D001786:Blood Glucose; D002543:Cerebral Hemorrhage / Q000209:etiology* / Q000517:prevention & control; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006801:Humans; D006943:Hyperglycemia / Q000503:physiopathology; D007269:Injections, Intra-Arterial; D008279:Magnetic Resonance Imaging; D018579:Patient Selection; D011237:Predictive Value of Tests; D012306:Risk; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage
D001786:Blood Glucose; D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator